Scaling With Autonomous AI for Diabetic Retinopathy Screening

In this episode, Dr. T.Y. Alvin Liu, Inaugural Director, James P Gills Jr MD and Heather Gills AI Innovation Center at Johns Hopkins Medicine shares his journey in healthcare AI, with a focus on image analysis and real-world applications.

Dr. Liu discusses the FDA-approved autonomous AI system for diabetic retinopathy screening, which enables early detection in primary care settings and improves screening adherence. He outlines successful AI implementations at Johns Hopkins, including prior authorization pilots using generative AI and the importance of operational understanding in deployment. He also discussed the intersection of value-based medicine and artificial intelligence, and the challenges of implementing successful AI programs. 

At the enterprise level, Dr. Liu emphasizes the need for strong AI governance to assess safety, effectiveness, and ROI. He outlines key challenges for AI startups, especially around reimbursement and regulation, and urges them to pursue sustainable business models. He also suggests closer collaboration among startups, VCs, and integrated health systems to bridge the gap between innovation and real-world adoption, essential for scaling AI responsibly and delivering long-term value in healthcare. Take a listen.